A systematic review and retrospective individual participant-level meta-analysis of 18 trials comprised of more than 1,700 participants found that initiating treatment with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) protects against kidney failure in patients with advanced chronic kidney disease (CKD).
Your privacy is our priority
- Hosted on Secure cloud-based hosting
- SOC II Type 1
- HIPAA compliant
- 2FA authentication
- End-to-end data encryption
- Your health data will not be sold or used without your consent. Ever.
